Table 2. Reason of AS discontinuation of “strict criteria” and “non-strict criteria” AS groups.
| Variable | Strict criteria AS (n=25) | Non strict criteria AS (n=29) | p-value | |||
|---|---|---|---|---|---|---|
| Discontinuation of AS | 8 (32.0) | 18 (62.1) | 0.03 | |||
| Protocol based discontinuation | 6 (24.0) | 15 (51.7) | 0.04 | |||
| Pathologic reclassification in follow-up biopsy | 5 (20.0) | 14 (48.2) | 0.05a | |||
| Pathologic Gleason upgrading in follow-up biopsy | 3 (12.0) | 8 (27.6) | 0.20a | |||
| Cancer founded more than 3 cores in follow-up biopsy | 4 (16.0) | 9 (31.0) | 0.22a | |||
| Clinical reclassification | 2 (8.0) | 1 (3.4) | 0.60a | |||
| New PIRADS 5 lesion during follow-up MRI | ||||||
| Patients request | 3 (12.0) | 3 (10.3) | >0.99a | |||
| Active surveillance adherence periods (mo) | 18.8±10.0 (12.0–26.0) | 13.8±8.3 (9.0–15.0) | <0.05 | |||
Values are presented as number (%) or mean±standard deviation (interquartile range).
AS, active surveillance; PIRADS, Prostate Imaging-Reporting and Data System; MRI, magnetic resonance imaging.
a:Fisher's exact test.